Secondary Logo

Journal Logo

EDITORIAL INTRODUCTIONS

Editorial introductions

Editor(s): Trotter, James F.; Fishbein, Thomas M.; Hanto, Douglas W.

Current Opinion in Organ Transplantation: April 2017 - Volume 22 - Issue 2 - p v-vi
doi: 10.1097/MOT.0000000000000401
  • Free

Current Opinion in Organ Transplantation was launched in 1996. It is part of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of organ transplantation is divided into 18 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Section Editors for this issue.

SECTION EDITORS

James F. Trotter

James F. Trotter

Dr Trotter finished medical school at Emory University and his internal medicine residency at Parkland Hospital at the University of Texas Southwestern Medical Center in Dallas before moving to Duke University Medical Center where he completed a fellowship on Gastroenterology and Hepatology. Thereafter, he accepted a staff position at the University of Colorado in Denver where he served as the Medical Director of liver transplantation. He currently serves as the Medical Director of liver transplantation at Baylor University Medical Center in Dallas as well as the head of the section of Hepatology. His clinical and research interests are in liver transplantation and the complications of end stage liver disease. He is a Deputy Editor of Liver Transplantation and is co-Editor of the book Medical Care of the Liver Transplant Recipient as well as an author of over 100 peer-reviewed papers.

Thomas M. Fishbein

Thomas M. Fishbein

Dr Thomas Fishbein is an internationally acclaimed leader in transplantation of the intestine, liver and hepatobiliary surgery. He studied at Georgetown University School of Medicine, then completed residency studies in surgery in Boston, followed by advanced fellowships in transplantation at the Mount Sinai Medical Center in New York and University of Pittsburgh. He was honored with Alpha Omega Alpha designation. He established himself as one of only a handful of international experts on intestinal transplantation, pioneering the use of new surgical techniques, immunosuppressive regimens and other treatments to improve outcomes. He was the first to use Sirolimus as primary immunosuppression for intestinal transplants, and to develop a protocol for inhibition of TNF alpha for chronic allograft enteropathy. More recently, he established the importance of innate immunity and alterations of the allograft microbiome to the understanding of transplant rejection, working with Dr Michael Zasloff, MD PhD, a renowned scientist in this area. Through these studies, the team at Georgetown University demonstrated fundamental similarities between transplant inflammation and the most fundamental inflammatory bowel diseases including Crohn's disease. Abnormalities of NOD2 signaling, the ileal dendritic cell response in transplantation, and an altered microbiome and metabolome suggest the transplant inflammatory process as “a Third Inflammatory Bowel Disease.” Dr Fishbein authored the only invited review on this topic published in the New England Journal of Medicine. His research has been funded by various organizations for over 13 years.

He is an expert in the most complex forms of liver transplantation, particularly among small children, and the most complex live donor and partial liver transplants. He has authored over 20 book chapters, over 120 major scientific publications and serves as Associate Editor of Clinical Transplantation, American Journal of Transplantation, and reviewer for many other journals. He has lectured widely internationally, and served as the President of the Intestinal Rehabilitation and Transplant Association. Among the many honors he has been awarded include the Lester Williams Teaching Award, the American Society of Transplant Surgeons-Wyeth faculty award, Collaborative Scientist Research Award, and the American Medical Association Burroughs-Wellcome Community Leadership Award. Currently, he is Professor of Surgery at Georgetown University and Executive Director of the Georgetown Transplant Institute, one of the nation's leading clinical, research and educational institutions in transplantation and hepatobiliary surgery.

Douglas W. Hanto

Douglas W. Hanto

Dr Hanto is currently a Professor of Surgery at Vanderbilt University School of Medicine, Director of the Vanderbilt Transplant Center, and Chief of Pediatric Liver Transplant at Monroe Carell Jr. Children's Hospital at Vanderbilt. Previously Dr Hanto was Associate Chairman of Surgery, Associate Surgeon-in-Chief, Vice Chair for Faculty Development and Academic Affairs, Chief of the Division of Transplantation within the Department of Surgery and Clinical Director of the Transplant Institute at Beth Israel Deaconess Medical Center in Boston, and Medical Director of the Advanced Vascular Care Center. He was also the Lewis Thomas Professor of Surgery at Harvard Medical School and is currently the Lewis Thomas Professor of Surgery Emeritus.

Dr Hanto received his MD from the University of Arizona College of Medicine, and his PhD in Surgery from the University of Minnesota. He completed his surgical training, research fellowship, and transplant fellowship at the University of Minnesota in Minneapolis.

Dr Hanto is an active clinical transplant and hepatobiliary surgeon and has been involved in patient care, clinical and basic research, and the training and mentoring of surgery residents and transplant fellows for more than 30 years. He has many original research contributions including the description of the clinical syndromes associated with post-transplant lymphoproliferative diseases (PTLD), their association with the Epstein-Barr virus (EBV), the morphological features that correlated with clinical presentation, and demonstrated that they were polyclonal B-cell proliferations that could evolve into monoclonal B-cell proliferations—resulting in improved techniques for preventing and treating these diseases. Dr Hanto's laboratory research is focused on the ability of carbon monoxide (CO) at low concentrations to be protective in animal models of ischemia-reperfusion injury and delayed graft function and in hepatic regeneration. Dr Hanto also has an interest in and has written on topics in transplant ethics (solicitation, organ allocation) and health care disparities, and along with Dr Keren Ladin, has investigated and written about the role of social networks and other factors in these disparities.

Dr Hanto has served on many journal editorial boards, is a senior director of the American Board of Surgery, and has served as Chair of the Ethics Committee of both The Transplantation Society (International) and the American Society of Transplantation. He has held many other leadership positions in the field of surgery and transplantation. He has published over 240 articles, book chapters, editorials, and reviews.

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.